Screener
Crinetics Pharmaceuticals CRNX Equity Method Income
Discontinued — last reported Q4 '25
Equity Method Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2025
- Accession
- 0001658247-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Loss before income taxes | (465,137) | (297,938) | (209,331) |
| Income tax expense | 180 | — | — |
| Loss before equity method investment | (465,317) | (297,938) | (209,331) |
| Loss on equity method investment | — | (470) | (5,198) |
| Net loss | $(465,317) | $(298,408) | $(214,529) |
| Net loss per share: | |||
| Net loss per share - basic and diluted | $(4.95) | $(3.69) | $(3.69) |
| Weighted average shares - basic and diluted | 94,057 | 80,783 | 58,071 |
Item 16. Form 10-K Summary
FAQ
- What is Crinetics Pharmaceuticals's equity method income?
- Crinetics Pharmaceuticals (CRNX) reported equity method income of $0 in Q4 2025.
- What does equity method income mean?
- The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.
Ask your AI about Crinetics Pharmaceuticals's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude